Investment analysts at BMO Capital Markets started coverage on shares of ObsEva (NASDAQ:OBSV) in a report issued on Monday. The firm set an “outperform” rating and a $20.00 price target on the stock. BMO Capital Markets’ target price points to a potential upside of 106.19% from the stock’s current price.

OBSV has been the subject of several other reports. Zacks Investment Research downgraded ObsEva from a “hold” rating to a “sell” rating in a research note on Saturday, August 19th. Credit Suisse Group initiated coverage on ObsEva in a research note on Monday, October 9th. They set an “outperform” rating and a $16.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $25.00 target price (down from $27.00) on shares of ObsEva in a research note on Wednesday, October 11th. Finally, Royal Bank Of Canada initiated coverage on ObsEva in a research note on Thursday, September 14th. They set an “outperform” rating and a $22.00 target price for the company. Seven research analysts have rated the stock with a buy rating, ObsEva currently has an average rating of “Buy” and an average price target of $19.00.

Shares of ObsEva (NASDAQ OBSV) opened at $9.70 on Monday. ObsEva has a one year low of $5.00 and a one year high of $14.69.

ObsEva (NASDAQ:OBSV) last posted its quarterly earnings data on Tuesday, November 14th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.01). The business’s quarterly revenue was up NaN% on a year-over-year basis. research analysts forecast that ObsEva will post -2.27 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. VHCP Management II LLC raised its stake in shares of ObsEva by 834.2% during the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock worth $11,407,000 after buying an additional 1,251,343 shares in the last quarter. Abingworth LLP purchased a new position in shares of ObsEva during the 3rd quarter worth approximately $3,480,000. Sphera Funds Management LTD. raised its stake in shares of ObsEva by 12.4% during the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after buying an additional 28,700 shares in the last quarter. Sectoral Asset Management Inc raised its stake in shares of ObsEva by 181.9% during the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after buying an additional 137,331 shares in the last quarter. Finally, Iguana Healthcare Management LLC raised its stake in shares of ObsEva by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after buying an additional 20,000 shares in the last quarter. 35.91% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “ObsEva (OBSV) Now Covered by BMO Capital Markets” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/06/obseva-obsv-now-covered-by-bmo-capital-markets.html.

About ObsEva

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva (NASDAQ:OBSV)

Receive News & Stock Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related stocks with our FREE daily email newsletter.